This site is only for UK healthcare professionals and contains promotional information.
Prescribing information can be found at the bottom of this page.

UP TO 5 YEARS OF PROVEN
PSORIASIS CONTROL FROM AN IL-231

5 reasons to make ILUMETRI® your IL-23 of choice for patients with moderate-to-severe psoriasis

CONFIDENCE IN SUSTAINED EFFICACY

for up to 5 years.1

+Button

IMPROVED – QUALITY OF LIFE

with more than 50% of patients (W28 responders) reporting that psoriasis no longer affected their lives after just 3 injections (DLQI 0/1 in 52% of n=299 patients).2
CONSISTENT, FAVOURABLE SAFETY PROFILE
confirmed by 5-year data, with low rates of AEs of special interest,* including severe infections, malignancies and MACE.1

CONVENIENT
– DOSING SCHEDULE

with only 4 injections per year during maintenance and flexible dosing to adapt to patient needs.3
MORE COST EFFECTIVE
than other biologics,4† with
flat pricing across doses.5
+Button

*AEs of special interest also included malignancies, NMSC, injection site reactions and drug-related hypersensitivity reactions.
†When assessed at Week 28, compared with other targeted treatments that are usually assessed between 12 weeks and 16 weeks (such as brodalumab, guselkumab, ixekizumab, infliximab and secukinumab).4

ILUMETRI® DELIVERS SUSTAINED EFFICACY for nearly 5 years1
The efficacy population included responder patients (≥75% improvement from baseline PASI score) at Week 28 who continuously received the same dose of ILUMETRI® 100 mg (n=329) and were followed-up until Week 244. Multiple imputation for missing data was used as the main efficacy analysis. Observed cases and non-responder imputation were employed as sensitivity analyses. Significantly more ILUMETRI® patients achieved PASI 75 at Week 12 vs. placebo in both studies (reSURFACE-1/2: 64%/61% [100 mg], 62%/66% [200 mg] vs. 6%/6% [placebo], p<0.0001) and vs. etanercept (reSURFACE-2: 61% [100 mg, p=0.001], 66% [200 mg, p<0.0001] vs. 48%). Significantly more ILUMETRI® patients achieved a PGA score of ‘clear’ or ‘minimal’, with ≥2-grade reduction from baseline at Week 12 in both studies vs. placebo (reSURFACE-1/2: 58%/55% [100 mg], 59%/59% [200 mg] vs. 7%/4% [placebo], p<0.0001), ILUMETRI® 200 mg (59%, p=0.0031) and ILUMETRI® 100 mg (55%, p=0.0663) vs. etanercept (48%). Step-down multiplicity strategy used.
ILUMETRI® OFFERS IMPROVED QUALITY OF LIFE with more than 50% of patients (Week 28 responders) reporting that psoriasis no longer affected their lives after just 3 injections (DLQI 0/1 in 52% of n=299 patients)2
Patients receiving ILUMETRI® improved their DLQI score (0/1)* over time3
Adapted from ILUMETRI® Summary of Product Characteristics.
Data shown are based on the full analysis set of randomised subjects receiving ILUMETRI® 100 mg with valid values for baseline and endpoint in reSURFACE 1; missing data have not been imputed.
Data from patients who achieved at least PASI 75 at Week 28 is shown for Week 52.2
*A DLQI score of 0 or 1 indicates no effect of psoriasis on quality of life. The DLQI score is the sum of the 10 individual question scores and ranges from 0 to 30, with lower scores indicating better quality of life.2

ILUMETRI® DEMONSTRATED A CONSISTENT, FAVOURABLE SAFETY PROFILE confirmed by 5-year data, with low rates of AEs of special interest,* including severe infections, malignancies and MACE1,7

Low rates of severe infections
  • Severe infection rates were low1
  • Candida infections were infrequent1,7

No increased risk or worsening events of IBD1,7

  • No exacerbations of pre-existing IBD1,7
No increased risk of malignancies1
  • Frequencies and exposure-adjusted rates of malignancies, NMSC and melanoma were low1
No increased risk of MACE1
  • Frequencies and exposure-adjusted rates
    were low1
Low rates of severe infections
  • Severe infection rates were low1
  • Candida infections were infrequent7,8
No increased risk or worsening events of IBD8
  • No exacerbations of pre-existing IBD8
No increased risk of malignancies1
  • Frequencies and exposure-adjusted rates of malignancies, NMSC and melanoma were low1
No increased risk of MACE1
  • Frequencies and exposure-adjusted rates were low1
*AEs of special interest also included malignancies, NMSC, injection site reactions and drug-related hypersensitivity reactions.
ILUMETRI® HAS A CONVENIENT DOSING SCHEDULE with only 4 injections per year during maintenance and flexible dosing to adapt to patient needs3

Dosing frequency may influence adherence and, ultimately, the likelihood of treatment success8

Please refer to approved Summary of Product Characteristics.
*Unopened pre-filled syringe. †After training in proper injection technique, patients may self-inject ILUMETRI®.

ILUMETRI® IS MORE COST EFFECTIVE THAN OTHER BIOLOGICS,4* with flat pricing across doses5

The only biologic where patients can continue treatment for 28 weeks before first efficacy assessment4,9–11

  • If <50% reduction in PASI score after starting treatment with ILUMETRI®, consider stopping
    between 12 weeks and 28 weeks4
  • Stop ILUMETRI® at Week 28 if the psoriasis has not responded adequately4
  • 75% reduction in the PASI score (PASI 75) from starting treatment, or
  • 50% reduction in the PASI score (PASI 50) and a
    5-point reduction in DLQI from starting treatment
NICE recommends ILUMETRI® as an option for treating plaque psoriasis in adults when:4
  • Disease is severe (total PASI score ≥10 and DLQI >10), and
  • The disease has not responded to other systemic treatments, including cyclosporin, methotrexate and phototherapy, or these treatments are contraindicated or not tolerated
  • The company provides the drug according to the commercial arrangement
A cost-effective use of NHS resources when response is assessed at Week 284
The only biologic where patients can continue treatment for 28 weeks before first efficacy assessment4,10–12
  • If <50% reduction in PASI score after starting treatment with ILUMETRI®, consider stopping between 12 weeks and 28 weeks4
  • Stop ILUMETRI® at Week 28 if the psoriasis has not responded adequately4
  • 75% reduction in the PASI score (PASI 75) from starting treatment, or
  • 50% reduction in the PASI score (PASI 50) and a 5-point reduction in DLQI from starting treatment
NICE recommends ILUMETRI® as an option for treating plaque psoriasis in adults when:4
  • Disease is severe (total PASI score ≥10 and DLQI >10), and
  • The disease has not responded to other systemic treatments, including cyclosporin, methotrexate and phototherapy, or these treatments are contraindicated or not tolerated
  • The company provides the drug according to the commercial arrangement
A cost-effective use of NHS resources when response is assessed at Week 284
*When assessed at Week 28, compared with other targeted treatments that are usually assessed between 12 weeks and 16 weeks (such as brodalumab, guselkumab, ixekizumab, infliximab and secukinumab).4

References

1. Thaçi D, et al. Br J Dermatol 2021. DOI: 10.1111/bjd.19866.
2. Reich K, et al. Lancet 2017;15:276–288.
3. ILUMETRI® Summary of Product Characteristics. Almirall.
4. NICE. Tildrakizumab for treating moderate to severe plaque psoriasis. Available at: https://www.nice.org.uk/guidance/ta575.
5. ILUMETRI® MIMS. Available at: https://www.mims.co.uk/drugs/skin/psoriasis-seborrhoeaactual-hyphenichthyosis/ilumetri.
6. Almirall. Data on file. IE-TIL-1900005.
7. Reich K, et al. Br J Dermatol 2020;182:605–617.
8. Zhang M, et al. J Drugs Dermatol 2017;16:220–226.
9. NICE. Risankizumab for treating moderate to severe plaque psoriasis. Available at: https://www.nice.org.uk/guidance/ta596.
10. NICE. Guselkumab for treating moderate to severe plaque psoriasis. Available at: https://www.nice.org.uk/guidance/ta521.
11. NICE. Ustekinumab for the treatment of adults with moderate to severe psoriasis. Available at: https://www.nice.org.uk/guidance/ta180.

 

UK-ILU-2100069 June 2021

Sites of interest

Almirall.co.uk

UK-ILU-2100103 February 2022

Prescribing Information

ILUMETRI®▼ (tildrakizumab)

Skilarence® (dimethyl fumarate)

Klisyri®▼ (tirbanibulin)

Cookies Policy

Privacy Policy UK

Terms of Use

©2021 Almirall
My Favorites